Market News AIOpen the app

Gain Therapeutics, Inc. finished a Phase 1b study of rexaceract, showing stable motor scores after 12 months.

TrialRead the original at SEC EDGAR
Good for GANX

Gain Therapeutics reported stable motor scores after 12 months among 13 patients, with no overall disease progression. One participant later diagnosed with MSA had a different marker change and no meaningful response, but the broader results and safety record support the company.

GANX · Gain Therapeutics, Inc.

AI read · Good for GANX

The AI's read

Stable motor scores and the reported safety record support an encouraging read of rexaceract's results. One participant later diagnosed with MSA had a different marker change and no meaningful response, so the findings did not apply equally to everyone.

Get alerts for GANX

Follow Gain Therapeutics, Inc. (GANX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GANX
Free on the App Store and Google Play, or on the web.